The Mammaprint test, developed by Agendia (http://www.agendia.com/pages/mammaprint/21.php), is used to predict whether early breast cancer is likely to spread (metastasize) to other parts of the body. This is accomplished by looking (at the molecular level) at the activity of 70 different genes known to be involved in the progression of cancer. The results group the cancers into 'low' or 'high' risk for spread of cancer and can be used to guide treatment decisions. The test was initially approved in 2007 (http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048477.htm).
The development of accurate molecular tests for drug sensitivity and prediction of disease progression is critical. These tests have the potential to spare patients treatments that are unlikely to work for their cancer and let them begin more effective treatments immediately. Essentially, the tests allow clinicians to treat each cancer case individually. These types of test will (and already have had) have a great impact on cancer survival and quality of life for patients.
The Mammaprint test, developed by Agendia (http://www.agendia.com/pages/mammaprint/21.php), is used to predict whether early breast cancer is likely to spread (metastasize) to other parts of the body. This is accomplished by looking (at the molecular level) at the activity of 70 different genes known to be involved in the progression of cancer. The results group the cancers into 'low' or 'high' risk for spread of cancer and can be used to guide treatment decisions. The test was initially approved in 2007 (http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048477.htm).
The development of accurate molecular tests for drug sensitivity and prediction of disease progression is critical. These tests have the potential to spare patients treatments that are unlikely to work for their cancer and let them begin more effective treatments immediately. Essentially, the tests allow clinicians to treat each cancer case individually. These types of test will (and already have had) have a great impact on cancer survival and quality of life for patients.
Call SHARE at: 866-891-2392
to speak directly to a trained breast cancer survivor for support and guidance.
3 Quick Ways You Can Help
1) Spread the word! Tell people you think might want some support. Tell medical professionals, health providers, and organizations.
2) Like us on Facebook and follow us on Twitter! 3) Volunteer - email us at volunteer@talkabouthealth.com for more information.
The development of accurate molecular tests for drug sensitivity and prediction of disease progression is critical. These tests have the potential to spare patients treatments that are unlikely to work for their cancer and let them begin more effective treatments immediately. Essentially, the tests allow clinicians to treat each cancer case individually. These types of test will (and already have had) have a great impact on cancer survival and quality of life for patients. The Mammaprint test, developed by Agendia (http://www.agendia.com/pages/mammaprint/21.php), is used to predict whether early breast cancer is likely to spread (metastasize) to other parts of the body. This is accomplished by looking (at the molecular level) at the activity of 70 different genes known to be involved in the progression of cancer. The results group the cancers into 'low' or 'high' risk for spread of cancer and can be used to guide treatment decisions. The test was initially approved in 2007 (http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048477.htm).
The development of accurate molecular tests for drug sensitivity and prediction of disease progression is critical. These tests have the potential to spare patients treatments that are unlikely to work for their cancer and let them begin more effective treatments immediately. Essentially, the tests allow clinicians to treat each cancer case individually. These types of test will (and already have had) have a great impact on cancer survival and quality of life for patients.
Note: Usernames have been made anonymous and profile images are not shown to protect the privacy of our members.